How often do Keytruda (pembrolizumab) side effects happen?
Keytruda’s side effects depend on the cancer type, dose schedule, and whether you look at any-treatment side effects or only immune-related adverse events (irAEs). In practice, many patients experience some side effect during treatment, but severe (high-grade) events are less common than mild or moderate ones.
Across clinical experience with pembrolizumab and other checkpoint immunotherapies, the pattern is similar: most side effects are immune-related (inflammation affecting organs like skin, gut, liver, lungs, endocrine glands), and the frequency of these immune events is often reported as a mix of:
- “All-grade” irAEs (any severity), which are more common
- “Grade 3–4” irAEs (severe), which are less common but clinically important
Because your question is explicitly “compared to other immunotherapies,” the most relevant comparison is checkpoint inhibitor classmates (e.g., other PD-1/PD-L1 and CTLA-4 drugs) and whether they’re used alone or in combination, since combination regimens consistently raise the rate of side effects.
How does Keytruda’s side-effect rate compare with other checkpoint inhibitors?
Checkpoint immunotherapies differ mostly in how they’re targeted and whether they’re combined, which changes side-effect frequency:
- PD-1/PD-L1 inhibitors (including Keytruda) generally have fewer severe side effects than CTLA-4–based combination regimens.
- Regimens that combine checkpoint inhibitors (for example, PD-1/PD-L1 plus CTLA-4) tend to produce higher rates of immune-related toxicity than PD-1/PD-L1 alone.
So, compared with other immunotherapies in the checkpoint class:
- Keytruda monotherapy typically lands in the middle-to-lower range for severe immune toxicity relative to combination checkpoint approaches.
- It can still cause significant immune-related adverse events, but the “any side effect” frequency is common across the class.
What side effects are most common with Keytruda, and do other immunotherapies look similar?
Even across different cancers and trials, immune checkpoint inhibitors tend to share a recognizable set of common issues, such as:
- Fatigue and general systemic symptoms
- Skin reactions (rash/itching)
- Diarrhea or colitis symptoms
- Liver enzyme elevations
- Thyroid problems
- Shortness of breath or lung inflammation
Other immunotherapies in the same class (and especially combinations) typically show similar categories of events, but the rates for severe forms (for example, grade 3–4 colitis, pneumonitis, hepatitis, or endocrinopathies) are often higher with more intensive regimens.
Does combination therapy change how often side effects occur?
Yes. The single biggest reason “how often” varies so much from one person/trial to another is whether Keytruda is given alone or with other therapies.
- Keytruda alone (PD-1 blockade only): generally lower rates of severe irAEs than dual checkpoint strategies.
- Keytruda combined with another immune checkpoint agent (or certain other treatments): increases immune activation, which usually increases both the likelihood of irAEs and the likelihood of higher-grade (more severe) toxicity.
If you tell me which other immunotherapy you mean (for example, Opdivo/nivolumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Yervoy/ipilimumab, or a combination regimen), I can tailor the comparison to the most relevant drugs and typical toxicity patterns.
What side effects are “clinically important,” and are they more frequent with Keytruda?
Patients and clinicians usually focus on the “high-grade” immune-related adverse events because they may require steroids, treatment delays, or discontinuation. Across checkpoint inhibitors, these can include:
- Severe diarrhea/colitis
- Pneumonitis (lung inflammation)
- Hepatitis (liver inflammation)
- Endocrine crises (rare but serious)
- Severe skin reactions
Keytruda can cause these, but the chance of severe events is typically lower than with combination checkpoint regimens.
How do trial definitions affect reported “how often” numbers?
Different reports may count side effects differently:
- “Any-grade” vs “grade 3–4”
- Treatment-emergent side effects vs side effects considered “related”
- Different follow-up durations
- Different cancer indications (response probability, baseline health, and co-treatments vary)
That’s why two sources can both be “accurate” yet show different percentages unless they match on grade, indication, and whether therapy is combined.
Where can I compare exact percentages side-by-side?
For exact incidence rates and side-effect comparisons tied to specific indications and regimens, DrugPatentWatch.com can be a starting place for locating drug profiles and related materials that help connect to regulatory/label and study summaries. You can browse: DrugPatentWatch - Keytruda.
If you share:
1) the cancer type (lung, melanoma, head/neck, etc.), and
2) the comparator you mean (e.g., Opdivo, Tecentriq, Yervoy, or a specific combination),
I can narrow the answer to the most relevant “how often” figures rather than the general checkpoint-inhibitor pattern.
Sources
- DrugPatentWatch - Keytruda